about
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureusDalbavancin in the treatment of complicated skin and soft-tissue infections: a reviewDalbavancin: a novel antimicrobialClinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)Enzymatic methods for glyco(diversification/randomization) of drugs and small moleculesAntibacterial natural products in medicinal chemistry--exodus or revival?Vancomycin analogs: Seeking improved binding of d-Ala-d-Ala and d-Ala-d-Lac peptides by side-chain and backbone modifications.Synthesis and evaluation of selected key methyl ether derivatives of vancomycin aglycon.Novel agents for the treatment of resistant Gram-positive infections.Novel antibacterial agents for the treatment of serious Gram-positive infections.A review of the current place of glycopeptides in turkish medical practiceTotal synthesis of [Ψ[C(═S)NH]Tpg4]vancomycin aglycon, [Ψ[C(═NH)NH]Tpg4]vancomycin aglycon, and related key compounds: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Natural products to drugs: natural product derived compounds in clinical trials.Tigecycline for the treatment of infections due to resistant Gram-positive organisms.Dalbavancin: a new option for the treatment of gram-positive infections.Understanding and manipulating glycopeptide pathways: the example of the dalbavancin precursor A40926.Review of dalbavancin, a novel semisynthetic lipoglycopeptide.Probing the role of the vancomycin e-ring aryl chloride: selective divergent synthesis and evaluation of alternatively substituted E-ring analogues.Total synthesis and evaluation of [Psi[CH2NH]Tpg4]vancomycin aglycon: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.Vancomycin resistance: are there better glycopeptides coming?Characterization of a regiospecific epivancosaminyl transferase GtfA and enzymatic reconstitution of the antibiotic chloroeremomycin.Synthesis and evaluation of vancomycin aglycon analogues that bear modifications in the N-terminal D-leucyl amino acid.Antibiotics: natural products essential to human health.Glycopeptide antibiotics: back to the future.Dalbavancin (BI-387) for the treatment of complicated skin and skin structure infection.Old and New Glycopeptide Antibiotics: Action and Resistance.Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic.Subinhibitory Dalbavancin Attenuates Exotoxin Production from Methicillin-sensitive and Methicillin-resistant Staphylococcus aureus in vitro.Role of surfactant and pH on dissolution properties of fenofibrate and glipizide--a technical note.Natural merodiploidy involving duplicated rpoB alleles affects secondary metabolism in a producer actinomycete.Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens.Antibakterielle Naturstoffe in der medizinischen Chemie – Exodus oder Renaissance?
P2860
Q24556635-AE6CA2DD-E1DC-4D1D-AF05-DB2E0B202D82Q24647429-8147CAD4-73C4-4BE8-9DCA-8B37D515C6E6Q24674841-FED7EEC5-63C2-4827-95A3-8EED4524015FQ26746208-DEAD9C25-81FB-479B-A44A-7CF8F13FD49CQ28247479-2FC5485F-35D7-431B-AF61-B96AB0B9B675Q28255204-6D36D36F-8AE4-4C0F-8086-8190D7AA2E06Q33944429-CB9947FA-241F-4962-8727-ECF481A28F9EQ34308628-BFFD37A2-0E00-48E2-98FA-CFAB5994E533Q35056042-461F712D-0158-4B26-A408-7F32413534F8Q35073345-9AFE558E-9B09-46E1-AD3D-D6D21D6A5C5BQ35134138-8CE0BDCD-219C-43AA-8693-A6845BE7CEACQ35683194-1DA8ED6F-C3F9-434A-A37F-5E12D5803B22Q36087066-E09F9FB4-AC4A-466A-ACF3-E61B2AFAD3A9Q36376443-7564B540-61C2-48CD-B42E-FDEC3D4F03D1Q36409507-AAD0BA79-9D8E-4BB3-9FDE-67CCE7EFA031Q36500241-E0B89086-BDC6-4699-AF0B-DC640A36C57CQ36802632-4CBAB3F9-169B-4AEC-BBCF-F55BA150C151Q36886883-B8328872-B71C-412D-A568-7F1FF54C540BQ36980378-9439177C-434C-458C-960D-8470334B37A0Q37119169-D68BC17A-C9D8-4407-9410-6B8F1C2CE6CAQ37340562-C29CAA77-6A54-4D72-8A96-98B36B89CAE1Q37357546-D179F0D7-360C-4913-B732-C54731E11A43Q37395641-F4083B7D-9A34-448B-9014-BE418F508DAEQ37416545-A87671A5-2BB0-4A4D-A938-B1965727F1F1Q38239460-D9A46455-F440-46FB-A394-EB16C67392E8Q38314386-D3725097-64B6-455C-9B6A-878315FB5C79Q38792892-BDA33CD6-CE0C-4B18-97C1-2ED1B3A5302EQ39164161-0ACCC988-E4E1-4F84-A7D1-12B95E7CD02AQ40065964-59D2A6B7-E21A-450C-ACE3-00BB1B35611EQ42110444-B7089347-BD3C-42B9-A0C0-ECBDEECF995AQ45230240-21D58326-2385-45B3-BF3A-4A7B9E4305C1Q45237058-7D60B7C9-EEBC-4FC6-B042-D42E1C697263Q56625626-1BC05944-21E1-4B4B-9D7F-E892AAB4F981
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Glycopeptide derivatives.
@ast
Glycopeptide derivatives.
@en
Glycopeptide derivatives.
@nl
type
label
Glycopeptide derivatives.
@ast
Glycopeptide derivatives.
@en
Glycopeptide derivatives.
@nl
prefLabel
Glycopeptide derivatives.
@ast
Glycopeptide derivatives.
@en
Glycopeptide derivatives.
@nl
P356
P1476
Glycopeptide derivatives.
@en
P2093
A Malabarba
R Ciabatti
P304
P356
10.2174/0929867013371716
P577
2001-12-01T00:00:00Z